Discovery of 2,3-Dihydro[1,4]dioxino[2,3-<i>g</i>]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency-Reference-Cited by-同舟云学术

Discovery of 2,3-Dihydro[1,4]dioxino[2,3-g]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency

Published:2024-03-29 Issue:7 Volume:67 Page:5502-5537
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chen Panpan¹²,Chen Cai¹,Zheng Yizheng³,Chen Fangjun¹,Liu Zhaojun³,Ren Shenhong³,Song Hangyu¹,Liu Tongdan³,Lu Zhipeng²,Sun Hongbin¹⁴^ORCID,Kong Yi³^ORCID,Yuan Haoliang¹⁴^ORCID

Affiliation:

1. Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China

2. School of Pharmacy, Nanjing Medical University, Nanjing 211166, China

3. School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China

4. Chongqing Innovation Institute of China Pharmaceutical University, Chongqing 401135, China

Funder

Natural Science Foundation of Chongqing Municipality

Natural Science Foundation of Jiangsu Province

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02099

Reference22 articles.

1. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013

2. Clopidogrel Two Doses Comparative 1-Year Assessment of Safety and Efficacy (COMPASS) Study in Japanese Patients with Ischemic Stroke

3. Aspirin Responsiveness in Acute Brain Ischaemia: Association with Stroke Severity and Clinical Outcome

4. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia.

5. Overcoming Clopidogrel Resistance: Discovery of Vicagrel as a Highly Potent and Orally Bioavailable Antiplatelet Agent